A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 277
- Registration Number
- NCT06052319
- Locations
- 🇺🇸
University of Florida Health Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Rio Grande Regional Hospital, McAllen, Texas, United States
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT05347485
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- Conditions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT05346835
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT04442737
- Locations
- 🇺🇸
Triple O Research Institute, West Palm Beach, Florida, United States
🇺🇸Midway Immunology and Research Center, Fort Pierce, Florida, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1056
- Registration Number
- NCT04372108
- Locations
- 🇺🇸
NMCP, Portsmouth, Virginia, United States
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 34244
- Registration Number
- NCT04276441
- Locations
- 🇺🇸
Evidation Health, San Mateo, California, United States
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT03825484
Sustainable Early Episode Clinic Study (SEEC)
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03571685
- Locations
- 🇺🇸
Sharp Outpatient Behavioral Health Clinic, San Diego, California, United States
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 386
- Registration Number
- NCT03464136
- Locations
- 🇺🇸
Ohio State University Hospital, Columbus, Ohio, United States
🇺🇸Florida Research Network, LLC, Gainesville, Florida, United States
🇺🇸Advanced Medical Research Center, Port Orange, Florida, United States
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
- Conditions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 2000
- Registration Number
- NCT03382613
- Locations
- 🇺🇸
Banner Baywood Medical Center, Mesa, Arizona, United States
🇺🇸St. Agnes Hospital, Baltimore, Maryland, United States
🇺🇸Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States